Fig. 3.

Tumor PD-L1 assessed on primary tumors and metastases and its association with survival outcome of the first PD-1-based ICI therapy. (A) Frequencies of tissue types used for tumor PD-L1 quantification in the total patient cohort; (B) frequencies of tumor PD-L1 expression determined on primary tumors versus metastases. (C, D) Kaplan–Meier survival curves showing progression-free (PFS) and overall survival (OS) dependent on tumor PD-L1 expression assessed on primary tumors (C) and metastases (D). (E, F) Multivariate Cox regression analysis of PFS and OS considering tumor PD-L1 expression determined on primary tumors (E) and metastases (F).